Quarterly ResultMay 11, 2026, 04:04 PM
Eikon Therapeutics Q1 Net Loss $83M; $596M Cash; Pipeline Progress
AI Summary
Eikon Therapeutics reported a net loss of $83.0 million for Q1 2026, compared to $74.5 million in the prior year. The company maintained a strong financial position with $596.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, expecting to fund operations into H2 2027. Eikon also announced significant progress across its oncology pipeline, with six abstracts accepted for the ASCO annual meeting highlighting new data from its lead programs EIK1001, EIK1003, and EIK1005.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $596.0 million as of March 31, 2026.
- Net loss attributable to common stockholders was $83.0 million for Q1 2026.
- R&D expenses increased 24% to $70.0 million in Q1 2026 from $56.6 million in Q1 2025.
- G&A expenses rose 17% to $17.3 million in Q1 2026 from $14.8 million in Q1 2025.
- Six abstracts accepted for the ASCO annual meeting, highlighting lead program data.
- EIK1001 advancing in Phase 2/3 trials for NSCLC and melanoma.
- EIK1003 advancing in Phase 1/2 trial for breast, ovarian, prostate, or pancreatic cancer.
- EIK1005 Phase 1/2 trial underway for advanced solid tumors, with dosing started in Feb 2026.